A pooled analysis of trials evaluating pembrolizumab monotherapy for NSCLC patients showed that patients aged ≥75 years with PD‐L1 TPS ≥50% treated with pembrolizumab as first‐line therapy had longer median OS than those treated with chemotherapy (27.4 vs. 7.7 months).26 Here, CD274 is linked to non-small cell lung carcinoma.